Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) approved Lexicon Pharmaceuticals’ Xermelo tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone couldn’t control properly.
Stellar Biotechnologies and biopharmaceuticals manufacturer Amaran Biotechnology have entered into an exclusive multi-year supply agreement regarding studies of immunotherapies for various cancers, including breast cancer.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
Another patent infringement against Teva has been filed in recent couple of months. Orexo AB has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma, Inc., and their parent company Teva.
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.
Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.
According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.
UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (3-5 September 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).
ASIT biotech, a Belgian clinical-stage biopharmaceutical company could soon market its gp-ASIT+ grass pollen product, as it showed positive results in Phase III clinical trial in grass pollen rhinitis.